As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > BUSINESS
BUSINESS
- Australia Accepts Shionogi’s NDA for Antibiotic Cefiderocol
December 4, 2024
- Forxiga Crowned in HP Market Promotion Ranking in October: Intage
December 4, 2024
- GE HealthCare to Fully Acquire Nihon Medi-Physics Next Year
December 3, 2024
- LEO Pharma’s Adtralza Pen Version Now Available in Japan
December 3, 2024
- Nichi-Iko Curbs Supply of Hirudoid Generic in Elective Care Fallout
December 3, 2024
- Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market
December 2, 2024
- J&J Makes Debut in Japan Lung Cancer Market with Rybrevant Launch
December 2, 2024
- Takeda Suspends Shipments of MR Vaccine as Quality Issue Drags On
December 2, 2024
- Sumitomo’s iPSC-Derived Retinal Sheet Set to Enter Clinic in US
December 2, 2024
- Alfresa Files ARS’ Epinephrine Nasal Spray in Japan
December 2, 2024
- Japan Pharma Market Projected to Cross 12 Trillion Yen in FY2029: IQVIA
November 29, 2024
- Leqembi Now Available in South Korea: Eisai
November 29, 2024
- Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
- Dermatologist Hails Bimzelx as New Option for HS: UCB Seminar
November 27, 2024
- Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
- Eisai, NCNP Tie Up for APOE Genetic Testing Research Sponsored by AMED
November 27, 2024
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Otsuka Files Esperion’s Cholesterol Fighter in Japan
November 27, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- ASKA, Renascience Wind Up PMS Drug Collab after PII Miss
November 26, 2024
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…